Pulse Biosciences develops CellFX nsPFA (nanosecond Pulsed Field Ablation) technology, which uses nanosecond pulses of electrical energy to non-thermally ablate cells while sparing surrounding tissue, with applications in the surgical and percutaneous treatment of atrial fibrillation. This Sr. Manager will execute clinical site development strategy across assigned sites, lead feasibility assessments and site qualification, build relationships with investigators and referral networks including electrophysiology labs and cardiology practices, and support site activation, enrollment, and performance monitoring.
Text as published by the employer. Always confirm details on the employer's site.